/ Published in 2013, Publication

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine

Safety and Immunogenicity of Human Papillomavirus-16/18 AS04-Adjuvanted Vaccine: A Randomized Trial in 10-25-Year-Old HIV-Seronegative African Girls and Young Women.

Sow PS, Watson-Jones D, Kiviat N, Changalucha J, Mbaye JD, Brown J, Bousso K, Kavishe B, Andreasen A, Toure M, Kapiga S, Mayaud P, Hayes R, Lebacq M, Herazeh M, Thomas F, Descamps D.

J Infect Dis 2013; 207:1753-63.

PMID:23242542

PMCID:PMC3636781

DOI:10.1093/infdis/jis619

Related citation

What you can read next

Does a school-based intervention to engage parents change opportunity for handwashing with soap at home? Practical experience from the Mikono Safi trial in Northwestern Tanzania.
he need to promote behaviour change at the cultural level
Empirical observations underestimate the proportion of human immunodeficiency virus infections attributable to sexually transmitted diseases in the Mwanza and Rakai sexually transmitted disease treatment trials: Simulation results